Cargando…
Bupi Yishen formula attenuates kidney injury in 5/6 nephrectomized rats via the tryptophan-kynurenic acid-aryl hydrocarbon receptor pathway
BACKGROUND: Bupi Yishen Formula (BYF), a patent traditional Chinese medicine (TCM) formulation, has been used in the clinical treatment of chronic kidney disease (CKD). However, the mechanism of action of BYF has not been fully elucidated. METHOD: To investigate the variation in the metabolic profil...
Autores principales: | Mo, Yenan, Jie, Xina, Wang, Lixin, Ji, Chunlan, Gu, Yueyu, Lu, Zhaoyu, Liu, Xusheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353787/ https://www.ncbi.nlm.nih.gov/pubmed/34376166 http://dx.doi.org/10.1186/s12906-021-03376-1 |
Ejemplares similares
-
Uncovering Bupi Yishen Formula Pharmacological Mechanisms Against Chronic Kidney Disease by Network Pharmacology and Experimental Validation
por: Zhang, Difei, et al.
Publicado: (2021) -
The Aryl Hydrocarbon Receptor in Chronic Kidney Disease: Friend or Foe?
por: Mo, Yenan, et al.
Publicado: (2020) -
Bupi Yishen Formula Versus Losartan for Non-Diabetic Stage 4 Chronic Kidney Disease: A Randomized Controlled Trial
por: Mao, Wei, et al.
Publicado: (2021) -
Rationale and design of the Helping Ease Renal failure with Bupi Yishen compared with the Angiotensin II Antagonist Losartan (HERBAAL) trial: a randomized controlled trial in non-diabetes stage 4 chronic kidney disease
por: Mao, Wei, et al.
Publicado: (2015) -
Kynurenic acid, an aryl hydrocarbon receptor ligand, is elevated in serum of Zucker fatty rats
por: Oxenkrug, G, et al.
Publicado: (2016)